{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T23:19:57Z","timestamp":1787527197731,"version":"build-2736575974"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":72,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08333-5","type":"journal-article","created":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T09:43:10Z","timestamp":1781343790000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A decoy virus strategy using plant-produced SARS-CoV-2 virus-like-particles to inhibit infection and lung injury"],"prefix":"10.1186","volume":"24","author":[{"given":"Jady","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Onodera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"McColman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Cramb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Khang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aye Aye","family":"Khine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Wen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ori D.","family":"Rotstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Mubareka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur S.","family":"Slutsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1714-3038","authenticated-orcid":false,"given":"Haibo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,13]]},"reference":[{"issue":"1","key":"8333_CR1","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/s41598-022-04883-y","volume":"12","author":"K-B Moon","year":"2022","unstructured":"Moon K-B, Jeon J-H, Choi H, Park J-S, Park S-J, Lee H-J, et al. Construction of SARS-CoV-2 virus-like particles in plant. Sci Rep. 2022;12(1):1005. https:\/\/doi.org\/10.1038\/s41598-022-04883-y.","journal-title":"Sci Rep"},{"key":"8333_CR2","doi-asserted-by":"publisher","first-page":"115503","DOI":"10.1016\/j.ejmech.2023.115503","volume":"257","author":"L Yang","year":"2023","unstructured":"Yang L, Wang Z. Bench-to-bedside: innovation of small molecule anti-SARS-CoV-2 drugs in China. Eur J Criminol Med Chem. 2023;257:115503. https:\/\/doi.org\/10.1016\/j.ejmech.2023.115503.","journal-title":"Eur J Criminol Med Chem"},{"issue":"23","key":"8333_CR3","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","volume":"386","author":"MJ Levin","year":"2022","unstructured":"Levin MJ, Ustianowski A, De Wit S, Launay O, Avila M, Templeton A, et al. Intramuscular AZD7442 (tixagevimab\u2013Cilgavimab) for prevention of Covid-19. N Engl J Med. 2022;386(23):2188\u2013200. https:\/\/doi.org\/10.1056\/NEJMoa2116620.","journal-title":"N Engl J Med"},{"issue":"5","key":"8333_CR4","doi-asserted-by":"publisher","first-page":"687","DOI":"10.7326\/M21-0111","volume":"174","author":"M Connors","year":"2021","unstructured":"Connors M, Graham BS, Lane HC, Fauci AS. SARS-CoV-2 vaccines: much accomplished, Much to learn. Ann Intern Med. 2021;174(5):687\u201390. https:\/\/doi.org\/10.7326\/M21-0111.","journal-title":"Ann Intern Med"},{"key":"8333_CR5","doi-asserted-by":"publisher","first-page":"1015355","DOI":"10.3389\/fimmu.2022.1015355","volume":"13","author":"Z Wang","year":"2022","unstructured":"Wang Z, Yang L, Song X-Q. Oral GS-441524 derivatives: next-generation inhibitors of SARS-CoV-2 RNA-dependent RNA polymerase. Front Immunol. 2022;13:1015355. https:\/\/doi.org\/10.3389\/fimmu.2022.1015355.","journal-title":"Front Immunol"},{"issue":"12","key":"8333_CR6","doi-asserted-by":"publisher","first-page":"113444","DOI":"10.1016\/j.celrep.2023.113444","volume":"42","author":"RJ Parsons","year":"2023","unstructured":"Parsons RJ, Acharya P. Evolution of the SARS-CoV-2 Omicron spike. Cell Rep. 2023;42(12):113444. https:\/\/doi.org\/10.1016\/j.celrep.2023.113444.","journal-title":"Cell Rep"},{"key":"8333_CR7","doi-asserted-by":"publisher","unstructured":"Yang S, Yu Y, Xu Y, Jian F, Song W, Yisimayi A, et al. Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure. The Lancet Infect Dis. 2024;24(2):e70\u201372. https:\/\/doi.org\/10.1016\/S1473-3099(23)00744-2.","DOI":"10.1016\/S1473-3099(23)00744-2"},{"key":"8333_CR8","doi-asserted-by":"publisher","unstructured":"Jian F, et al. Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN.1. bioRxiv. 2024;2024https:\/\/doi.org\/10.1101\/2024.04.19.590276.","DOI":"10.1101\/2024.04.19.590276"},{"key":"8333_CR9","doi-asserted-by":"publisher","unstructured":"Li P, et al. Characteristics of JN.1-derived SARS-CoV-2 subvariants SLip, FLiRT, and KP.2 in neutralization escape, infectivity and membrane fusion. BioRxiv Prepr Serv Biol. 2024.05.20.595020 (2024. https:\/\/doi.org\/10.1101\/2024.05.20.595020.","DOI":"10.1101\/2024.05.20.595020"},{"issue":"2","key":"8333_CR10","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41579-022-00809-7","volume":"21","author":"M Cox","year":"2023","unstructured":"Cox M, Peacock TP, Harvey WT, Hughes J, Wright DW, Willett BJ, et al. SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies. Nat Rev Microbiol. 2023;21(2):112\u201324. https:\/\/doi.org\/10.1038\/s41579-022-00809-7.","journal-title":"Nat Rev Microbiol"},{"issue":"2","key":"8333_CR11","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.cell.2022.12.018","volume":"186","author":"Q Wang","year":"2023","unstructured":"Wang Q, Iketani S, Li Z, Liu L, Guo Y, Huang Y, et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell. 2023;186(2):279\u201386.e8. https:\/\/doi.org\/10.1016\/j.cell.2022.12.018.","journal-title":"Cell"},{"key":"8333_CR12","doi-asserted-by":"publisher","unstructured":"Li L, Chen X, Wang Z, Li Y, Wang C, Jiang L, et al. Breakthrough infection elicits hypermutated IGHV3-53\/3-66 public antibodies with broad and potent neutralizing activity against SARS-CoV-2 variants including the emerging EG.5 lineages. PLoS Pathog. 2023;19(12):e1011856. https:\/\/doi.org\/10.1371\/journal.ppat.1011856.","DOI":"10.1371\/journal.ppat.1011856"},{"issue":"14","key":"8333_CR13","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1001\/jama.1982.03320390074052","volume":"247","author":"S Krugman","year":"1982","unstructured":"Krugman S. The newly licensed hepatitis B vaccine. Characteristics and indications for use. JAMA. 1982;247(14):2012\u201315. https:\/\/doi.org\/10.1001\/jama.1982.03320390074052.","journal-title":"JAMA"},{"issue":"1","key":"8333_CR14","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1080\/14760584.2023.2211153","volume":"22","author":"X Guan","year":"2023","unstructured":"Guan X, Yang Y, Du L. Advances in SARS-CoV-2 receptor-binding domain-based COVID-19 vaccines. Expert Rev Vaccines. 2023;22(1):422\u201339. https:\/\/doi.org\/10.1080\/14760584.2023.2211153.","journal-title":"Expert Rev Vaccines"},{"issue":"4","key":"8333_CR15","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1021\/cb600489g","volume":"2","author":"EB Puffer","year":"2007","unstructured":"Puffer EB, Pontrello JK, Hollenbeck JJ, Kink JA, Kiessling LL. Activating B cell signaling with defined multivalent ligands. ACS Chem Biol. 2007;2(4):252\u201362. https:\/\/doi.org\/10.1021\/cb600489g.","journal-title":"ACS Chem Biol"},{"issue":"7314","key":"8333_CR16","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nature09357","volume":"467","author":"J Yang","year":"2010","unstructured":"Yang J, Reth M. Oligomeric organization of the B-cell antigen receptor on resting cells. Nature. 2010;467(7314):465\u201369. https:\/\/doi.org\/10.1038\/nature09357.","journal-title":"Nature"},{"issue":"1","key":"8333_CR17","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/eji.200939559","volume":"40","author":"SA Keller","year":"2010","unstructured":"Keller SA, Schwarz K, Manolova V, von Allmen CE, Kinzler MG, Bauer M, et al. Innate signaling regulates cross-priming at the level of DC licensing and not antigen presentation. Eur J Immunol. 2010;40(1):103\u201312. https:\/\/doi.org\/10.1002\/eji.200939559.","journal-title":"Eur J Immunol"},{"issue":"8","key":"8333_CR18","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1097\/CJI.0b013e3181f1d614","volume":"33","author":"DE Speiser","year":"2010","unstructured":"Speiser DE, Schwarz K, Baumgaertner P, Manolova V, Devevre E, Sterry W, et al. Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. J Educ Chang Immunother. 2010;33(8):848. https:\/\/doi.org\/10.1097\/CJI.0b013e3181f1d614.","journal-title":"J Educ Chang Immunother"},{"issue":"11","key":"8333_CR19","doi-asserted-by":"publisher","first-page":"9743","DOI":"10.1021\/nn403085w","volume":"7","author":"NM Molino","year":"2013","unstructured":"Molino NM, Anderson AKL, Nelson EL, Wang S-W. Biomimetic protein nanoparticles facilitate enhanced dendritic cell activation and cross-presentation. ACS Nano. 2013;7(11):9743\u201352. https:\/\/doi.org\/10.1021\/nn403085w.","journal-title":"ACS Nano"},{"key":"8333_CR20","doi-asserted-by":"publisher","unstructured":"Smit MJ, Sander AF, Ariaans MBPA, Fougeroux C, Heinzel C, Fendel R, et al. First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2. LancetThe Lancet Microbe. 2023;4(3):e140\u201348. https:\/\/doi.org\/10.1016\/S2666-5247(22)00337-8.","DOI":"10.1016\/S2666-5247(22)00337-8"},{"issue":"1","key":"8333_CR21","doi-asserted-by":"publisher","first-page":"19234","DOI":"10.1038\/srep19234","volume":"6","author":"KD Brune","year":"2016","unstructured":"Brune KD, Leneghan DB, Brian IJ, Ishizuka AS, Bachmann MF, Draper SJ, et al. Plug-and-display: decoration of virus-like particles via isopeptide bonds for modular immunization. Sci Rep. 2016;6(1):19234. https:\/\/doi.org\/10.1038\/srep19234.","journal-title":"Sci Rep"},{"issue":"5","key":"8333_CR22","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.cell.2020.10.043","volume":"183","author":"AC Walls","year":"2020","unstructured":"Walls AC, Fiala B, Sch\u00e4fer A, Wrenn S, Pham MN, Murphy M, et al. Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2. Cell. 2020;183(5):1367\u201382.e17. https:\/\/doi.org\/10.1016\/j.cell.2020.10.043.","journal-title":"Cell"},{"key":"8333_CR23","doi-asserted-by":"publisher","unstructured":"Jacob-Dolan C, Yu J, McMahan K, Giffin V, Chandrashekar A, Martinot AJ, et al. Immunogenicity and protective efficacy of GBP510\/AS03 vaccine against SARS-CoV-2 delta challenge in rhesus macaques. NPJ Vaccines. 2023;8(1). https:\/\/doi.org\/10.1038\/s41541-023-00622-0.","DOI":"10.1038\/s41541-023-00622-0"},{"key":"8333_CR24","doi-asserted-by":"publisher","first-page":"101569","DOI":"10.1016\/j.eclinm.2022.101569","volume":"51","author":"JY Song","year":"2022","unstructured":"Song JY, Choi WS, Heo JY, Lee JS, Jung DS, Kim S-W, et al. Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: a randomised, placebo-controlled, observer-blinded phase 1\/2 trial. EClinicalMedicine. 2022;51:101569. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101569.","journal-title":"EClinicalMedicine"},{"key":"8333_CR25","doi-asserted-by":"publisher","first-page":"102140","DOI":"10.1016\/j.eclinm.2023.102140","volume":"64","author":"JY Song","year":"2023","unstructured":"Song JY, Choi WS, Heo JY, Kim EJ, Lee JS, Jung DS, et al. Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: interim results of a randomised, active-controlled, observer-blinded, phase 3 trial. eClinicalmedicine. 2023;64:102140. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102140.","journal-title":"eClinicalmedicine"},{"issue":"5","key":"8333_CR26","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/j.1467-7652.2009.00496.x","volume":"8","author":"MA D\u2019Aoust","year":"2010","unstructured":"D\u2019Aoust MA, Couture MM-J, Charland N, Tr\u00e9panier S, Landry N, Ors F, et al. The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza. Plant Biotechnol J. 2010;8(5):607\u201319. https:\/\/doi.org\/10.1111\/j.1467-7652.2009.00496.x.","journal-title":"Plant Biotechnol J"},{"issue":"2","key":"8333_CR27","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41423-021-00809-2","volume":"19","author":"S Pillet","year":"2022","unstructured":"Pillet S, Arunachalam PS, Andreani G, Golden N, Fontenot J, Aye PP, et al. Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primates. Cell Mol Immunol. 2022;19(2):222\u201333. https:\/\/doi.org\/10.1038\/s41423-021-00809-2.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"8333_CR28","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41541-022-00561-2","volume":"7","author":"N Charland","year":"2022","unstructured":"Charland N, Gobeil P, Pillet S, Boulay I, S\u00e9guin A, Makarkov A, et al. Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in adults with and without comorbidities. NPJ Vaccines. 2022;7(1):142. https:\/\/doi.org\/10.1038\/s41541-022-00561-2.","journal-title":"NPJ Vaccines"},{"issue":"6","key":"8333_CR29","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/s41591-021-01370-1","volume":"27","author":"BJ Ward","year":"2021","unstructured":"Ward BJ, Gobeil P, S\u00e9guin A, Atkins J, Boulay I, Charbonneau P-Y, et al. Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19. Nat Med. 2021;27(6):1071\u201378. https:\/\/doi.org\/10.1038\/s41591-021-01370-1.","journal-title":"Nat Med"},{"issue":"30","key":"8333_CR30","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1016\/j.vaccine.2022.05.046","volume":"40","author":"C Dub\u00e9","year":"2022","unstructured":"Dub\u00e9 C, Paris-Robidas S, Andreani G, Gutzeit C, D\u2019Aoust M-A, Ward BJ, et al. Broad neutralization against SARS-CoV-2 variants induced by ancestral and B.1.351 AS03-adjuvanted recombinant plant-derived virus-like particle vaccines. Vaccine. 2022;40(30):4017\u201325. https:\/\/doi.org\/10.1016\/j.vaccine.2022.05.046.","journal-title":"Vaccine"},{"key":"8333_CR31","doi-asserted-by":"publisher","unstructured":"Benen TD, Tonks P, Kliche A, Kapzan R, Heeney JL, Wagner R. Development and immunological assessment of VLP-based immunogens exposing the membrane-proximal region of the HIV-1 gp41 protein. J Biomed Sci. 2014;21(1). https:\/\/doi.org\/10.1186\/s12929-014-0079-x.","DOI":"10.1186\/s12929-014-0079-x"},{"key":"8333_CR32","doi-asserted-by":"publisher","unstructured":"Thompson EA, Ols S, Miura K, Rausch K, Narum DL, Sp\u00e5ngberg M, et al. TLR-adjuvanted nanoparticle vaccines differentially influence the quality and longevity of responses to malaria antigen Pfs25. JCI Insight. 2018;3(10):e120692. https:\/\/doi.org\/10.1172\/jci.insight.120692.","DOI":"10.1172\/jci.insight.120692"},{"key":"8333_CR33","doi-asserted-by":"publisher","unstructured":"Hager KJ, et al. Efficacy and Safety of a recombinant plant-based adjuvanted Covid-19 vaccine. N Engl J Med. 2022;NEJMoa2201300. https:\/\/doi.org\/10.1056\/NEJMoa2201300.","DOI":"10.1056\/NEJMoa2201300"},{"issue":"2","key":"8333_CR34","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3390\/vaccines13020191","volume":"13","author":"D-K Vo","year":"2025","unstructured":"Vo D-K, Trinh KTL. Molecular farming for immunization: current Advances and future prospects in plant-produced vaccines. Nato Adv Sci Inst Se. 2025;13(2):191. https:\/\/doi.org\/10.3390\/vaccines13020191.","journal-title":"Nato Adv Sci Inst Se"},{"issue":"10","key":"8333_CR35","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1021\/acsinfecdis.2c00217","volume":"8","author":"CS Kumar","year":"2022","unstructured":"Kumar CS, Singh B, Rizvi ZA, Parray HA, Verma JK, Ghosh S, et al. Virus-like particles of SARS-CoV-2 as virus surrogates: morphology, immunogenicity, and internalization in neuronal cells. ACS Infect Dis. 2022;8(10):2119\u201332. https:\/\/doi.org\/10.1021\/acsinfecdis.2c00217.","journal-title":"ACS Infect Dis"},{"issue":"16","key":"8333_CR36","doi-asserted-by":"publisher","first-page":"4167","DOI":"10.1039\/D3NA00190C","volume":"5","author":"S McColman","year":"2023","unstructured":"McColman S, Shkalla K, Sidhu P, Liang J, Osman S, Kovacs N, et al. SARS-CoV-2 virus-like-particles via liposomal reconstitution of spike glycoproteins. Nanoscale Adv. 2023;5(16):4167\u201381. https:\/\/doi.org\/10.1039\/D3NA00190C.","journal-title":"Nanoscale Adv"},{"issue":"4","key":"8333_CR37","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3390\/antib11040076","volume":"11","author":"S Hirschberg","year":"2022","unstructured":"Hirschberg S, Bauer H, Kamhieh-Milz J, Ringel F, Harms C, Eddin OK, et al. SARS-CoV-2 virus-like particles (VLPs) specifically detect Humoral immune reactions in an ELISA-Based platform. Antibodies Basel Switz. 2022;11(4):76. https:\/\/doi.org\/10.3390\/antib11040076.","journal-title":"Antibodies Basel Switz"},{"key":"8333_CR38","doi-asserted-by":"publisher","first-page":"100103","DOI":"10.1074\/jbc.RA120.016148","volume":"296","author":"CB Plescia","year":"2021","unstructured":"Plescia CB, David EA, Patra D, Sengupta R, Amiar S, Su Y, et al. SARS-CoV-2 viral budding and entry can be modeled using BSL-2 level virus-like particles. J Biol Chem. 2021;296:100103. https:\/\/doi.org\/10.1074\/jbc.RA120.016148.","journal-title":"J Biol Chem"},{"key":"8333_CR39","doi-asserted-by":"publisher","first-page":"100440","DOI":"10.1016\/j.jvacx.2024.100440","volume":"16","author":"MS Taghizadeh","year":"2024","unstructured":"Taghizadeh MS, Niazi A, Afsharifar A. Virus-like particles (VLPs): a promising platform for combating against Newcastle disease virus. Vaccine. 2024;16:100440. https:\/\/doi.org\/10.1016\/j.jvacx.2024.100440.","journal-title":"Vaccine"},{"issue":"6575","key":"8333_CR40","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1126\/science.abl6184","volume":"374","author":"AM Syed","year":"2021","unstructured":"Syed AM, Taha TY, Tabata T, Chen IP, Ciling A, Khalid MM, et al. Rapid assessment of SARS-CoV-2\u2013evolved variants using virus-like particles. Science. 2021;374(6575):1626\u201332. https:\/\/doi.org\/10.1126\/science.abl6184.","journal-title":"Science"},{"issue":"10","key":"8333_CR41","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.3390\/v14102087","volume":"14","author":"M Jaron","year":"2022","unstructured":"Jaron M, Lehky M, Zar\u00e0 M, Zaydowicz CN, Lak A, Ballmann R, et al. Baculovirus-Free SARS-CoV-2 Virus-like particle production in insect cells for rapid neutralization assessment. Viruses. 2022;14(10):2087. https:\/\/doi.org\/10.3390\/v14102087.","journal-title":"Viruses"},{"issue":"5","key":"8333_CR42","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/ncb3510","volume":"19","author":"Y-W Chen","year":"2017","unstructured":"Chen Y-W, Huang SX, de Carvalho ALRT, Ho S-H, Islam MN, Volpi S, et al. A three-dimensional model of human lung development and disease from pluripotent stem cells. Nat Cell Biol. 2017;19(5):542\u201349. https:\/\/doi.org\/10.1038\/ncb3510.","journal-title":"Nat Cell Biol"},{"issue":"8","key":"8333_CR43","doi-asserted-by":"publisher","first-page":"107470","DOI":"10.1016\/j.isci.2023.107470","volume":"26","author":"Y Onodera","year":"2023","unstructured":"Onodera Y, Liang J, Li Y, Griffin B, Thanabalasingam T, Lu C, et al. Inhalation of ACE2 as a therapeutic target on sex-bias differences in SARS-CoV-2 infection and variant of concern. iScience. 2023;26(8):107470. https:\/\/doi.org\/10.1016\/j.isci.2023.107470.","journal-title":"iScience"},{"issue":"10","key":"8333_CR44","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1110\/ps.04688204","volume":"13","author":"H Fischer","year":"2004","unstructured":"Fischer H, Polikarpov I, Craievich AF. Average protein density is a molecular-weight-dependent function. Protein Sci. 2004;13(10):2825\u201328. https:\/\/doi.org\/10.1110\/ps.04688204.","journal-title":"Protein Sci"},{"issue":"1","key":"8333_CR45","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/j.1432-1033.1969.tb00651.x","volume":"10","author":"AS Spirin","year":"2005","unstructured":"Spirin AS. The second sir Hans Krebs Lecture. Eur J Biochem. 2005;10(1):20\u201335. https:\/\/doi.org\/10.1111\/j.1432-1033.1969.tb00651.x.","journal-title":"Eur J Biochem"},{"issue":"48","key":"8333_CR46","doi-asserted-by":"publisher","first-page":"20550","DOI":"10.1039\/D1NR06137B","volume":"13","author":"S McColman","year":"2021","unstructured":"McColman S, Li R, Osman S, Bishop A, Wilkie KP, Cramb DT. Serum proteins on nanoparticles: early stages of the \u201cprotein corona\u201d. Nanoscale. 2021;13(48):20550\u201363. https:\/\/doi.org\/10.1039\/D1NR06137B.","journal-title":"Nanoscale"},{"key":"8333_CR47","doi-asserted-by":"publisher","unstructured":"Chera A, Tanca A. Remdesivir: the first FDA-approved anti-COVID-19 treatment for young children. Discoveries. 2022;10(2):e151. https:\/\/doi.org\/10.15190\/d.2022.10.","DOI":"10.15190\/d.2022.10"},{"key":"8333_CR48","doi-asserted-by":"publisher","unstructured":"Padasas BT, Espa\u00f1o E, Kim S-H, Song Y, Lee C-K, Kim J-K. COVID-19 Therapeutics: an update on effective treatments against infection with SARS-CoV-2 variants. Immune Netw. 2023;23(2):e13. https:\/\/doi.org\/10.4110\/in.2023.23.e13.","DOI":"10.4110\/in.2023.23.e13"},{"issue":"5","key":"8333_CR49","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1056\/NEJMoa2208822","volume":"388","author":"Z Cao","year":"2023","unstructured":"Cao Z, Gao W, Bao H, Feng H, Mei S, Chen P, et al. VV116 versus nirmatrelvir\u2013ritonavir for Oral treatment of Covid-19. N Engl J Med. 2023;388(5):406\u201317. https:\/\/doi.org\/10.1056\/NEJMoa2208822.","journal-title":"N Engl J Med"},{"issue":"4","key":"8333_CR50","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s00134-020-05985-9","volume":"46","author":"H Zhang","year":"2020","unstructured":"Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46(4):586\u201390. https:\/\/doi.org\/10.1007\/s00134-020-05985-9.","journal-title":"Intensive Care Med"},{"issue":"1","key":"8333_CR51","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1186\/s13054-020-03398-0","volume":"24","author":"JF Bermejo-Martin","year":"2020","unstructured":"Bermejo-Martin JF, Gonz\u00e1lez-Rivera M, Almansa R, Micheloud D, Tedim AP, Dom\u00ednguez-Gil M, et al. Viral RNA load in plasma is associated with critical illness and a dysregulated host response in COVID-19. Crit Care. 2020;24(1):691. https:\/\/doi.org\/10.1186\/s13054-020-03398-0.","journal-title":"Crit Care"},{"issue":"1","key":"8333_CR52","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s10529-021-03211-0","volume":"44","author":"F Hemmati","year":"2022","unstructured":"Hemmati F, Hemmati-Dinarvand M, Karimzade M, Rutkowska D, Eskandari MH, Khanizadeh S, et al. Plant-derived VLP: a worthy platform to produce vaccine against SARS-CoV-2. Biotechnol Lett. 2022;44(1):45\u201357. https:\/\/doi.org\/10.1007\/s10529-021-03211-0.","journal-title":"Biotechnol Lett"},{"issue":"12","key":"8333_CR53","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.3390\/vaccines9121409","volume":"9","author":"WA Prates-Syed","year":"2021","unstructured":"Prates-Syed WA, Chaves LCS, Crema KP, Vuitika L, Lira A, C\u00f4rtes N, et al. VLP-Based COVID-19 vaccines: an adaptable technology against the threat of New variants. Nato Adv Sci Inst Se. 2021;9(12):1409. https:\/\/doi.org\/10.3390\/vaccines9121409.","journal-title":"Nato Adv Sci Inst Se"},{"issue":"1","key":"8333_CR54","doi-asserted-by":"publisher","first-page":"26","DOI":"10.4161\/hv.22218","volume":"9","author":"Q Chen","year":"2013","unstructured":"Chen Q, Lai H. Plant-derived virus-like particles as vaccines. Hum Vaccines Immunotherapeutics. 2013;9(1):26\u201349. https:\/\/doi.org\/10.4161\/hv.22218.","journal-title":"Hum Vaccines Immunotherapeutics"},{"issue":"12","key":"8333_CR55","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s12033-021-00381-0","volume":"63","author":"L Sethi","year":"2021","unstructured":"Sethi L, Kumari K, Dey N. Engineering of plants for efficient production of Therapeutics. Mol Biotechnol. 2021;63(12):1125\u201337. https:\/\/doi.org\/10.1007\/s12033-021-00381-0.","journal-title":"Mol Biotechnol"},{"issue":"1","key":"8333_CR56","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.vaccine.2023.11.048","volume":"42","author":"AB Gashti","year":"2024","unstructured":"Gashti AB, Agbayani G, Hrapovic S, Nassoury N, Coulombe N, Dudani R, et al. Production, purification and immunogenicity of gag virus-like particles carrying SARS-CoV-2 components. Vaccine. 2024;42(1):40\u201352. https:\/\/doi.org\/10.1016\/j.vaccine.2023.11.048.","journal-title":"Vaccine"},{"issue":"5","key":"8333_CR57","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1128\/CVI.00382-07","volume":"15","author":"K Broos","year":"2008","unstructured":"Broos K, Janssens ME, De Goeyse I, Vanlandschoot P, Leroux-Roels G, Geysen D, et al. Comparison of serum Humoral responses induced by Oral immunization with the hepatitis B virus core antigen and the cholera toxin B subunit. Clin Vaccine Immunol. 2008;15(5):852\u201358. https:\/\/doi.org\/10.1128\/CVI.00382-07.","journal-title":"Clin Vaccine Immunol"},{"issue":"2","key":"8333_CR58","doi-asserted-by":"publisher","first-page":"36","DOI":"10.29245\/2578-3009\/2018\/2.1118","volume":"2","author":"F Deng","year":"2018","unstructured":"Deng F. Advances and challenges in enveloped virus-like particle (VLP)-based vaccines. J Immunological Sci. 2018;2(2):36\u201341. https:\/\/doi.org\/10.29245\/2578-3009\/2018\/2.1118.","journal-title":"J Immunological Sci"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08333-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08333-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08333-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T23:01:01Z","timestamp":1787526061000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08333-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,13]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8333"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08333-5","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,13]]},"assertion":[{"value":"27 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have viewed and agreed to publish this paper.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Virus-like-particles were generously provided by Medicago Inc. All authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1080"}}